Medicines for Europe
| Formation | 1993 |
|---|---|
| Headquarters | Rue d'Arlon, 50 B-1000 Brussels, Belgium |
Membership | Companies and National Associations Full Members (May 2013) |
President (Executive Comity) | Jacek Glinka |
| Website |
www |
Medicines for Europe is the new name of the European Generic Medicines Association (EGA) as of 11 March 2016. Representing the pharmaceutical companies supplying the largest share of medicines across Europe, Medicines for Europe is the voice of the generic, biosimilar and industries in Europe and a leading partner providing better health and better access to all European patients.
Medicines for Europe is at the forefront of providing high-quality affordable Medicines to millions of Europeans and stimulating competitiveness and innovation in the pharmaceutical sector. The association’s headquarters are located in at the Brussels Maison Européenne de la Protection Sociale, which is a two-minute walk from the European Parliament. Medicines for Europe has subscribed to the Transparency Register[1] set up and operated by the European Parliament and the European Commission.[2]
Purpose and objectives
The objectives of the Association are, without any profit purpose, to represent, support and develop the common scientific and technical interests of the generic pharmaceutical industry and the biosimilar industry or national or European associations of such, firms, companies or other legal bodies active in the generic pharmaceutical or the biosimilar industries.[3] Those interests shall include, but shall not be restricted to, developments within the European Union, Europe as a whole and relations between the European Union and third countries.[4][5][6]
For avoidance of doubt, the objectives shall include, but shall not be limited to:
- to monitor, study and analyse scientific and technical subjects of common interest to the members
- to encourage the formation of generic pharmaceutical and biosimilar associations in countries where they do not yet exist
- to inform the members of all trends and developments of common interest to the members
- to develop, co-ordinate and implement common positions of the members
- to support any European or international authority in respect of issues of common interest and, where necessary, to make representations to such authorities
- to inform, when necessary, the general public of issues of common interest to the members
- to foster and maintain contacts with European associations and institutions representing interests relevant to the generics and biosimilar industries
- to co-operate with national associations of generic and biosimilar producers
- to maintain relations with professional organisations concerned with health
- and lastly, through its general activities, to seek to promote progress in the generic pharmaceutical and biosimilar industries by quality improvements in products
Membership
The Association is composed of full members and affiliate members. Full membership is open to companies and national associations. Applications for full or affiliate membership by companies are understood to come from the mother company. A company, member or not of a national association member of the Association, is also entitled to apply to join directly as member of the Association. Parallel importers and companies which are subsidiaries of wholesaler groups cannot join the Association as their core interests are not those of the European generic or biosimilar industry. The quality of member of the Association is personal and may not be assigned to a third party. The minimum number of members cannot be less than six. The number of full members cannot be less than four. All applicants for membership (and once admitted, members), must, at all times: a) be validly incorporated under the laws and customs of their country of origin and b) abide with the anti-trust guidelines of the Association, its Articles of Association, its Internal Regulations (including its Code of Conduct) and the decisions of its bodies. [7]
History
Medicines for Europe began over 20 years ago as the European Generics Medicines Association (EGA) with the goal of representing the emerging generic industry, and later growing to include biosimilar medicines to its portfolio.
Greg Perry established the European Generic medicines Association (EGA) in 1993 and served as its full-time director general until December 2012. Since September 2013 Adrian van den Hoven is the new EGA's director general.[8]
Annual Conferences
Medicines for Europe organises several conferences per year, including Regulatory and Scientific Affairs, Pharmacovigilance, Legal Affairs, International Biosimilar Medicines conferences. The Annual Conference of the Association includes topics covering new developments and challenges in the generic medicines industry, developments and trends in the European generics market, the evolution and growth of the global generics industry, and the challenges facing the industry.[9][10]
References
- ↑
- ↑ Joint EGA & GPHA Response to the EU-US High Level Working Group on Jobs & Growth on Regulatory Issues
- ↑ Generic medicines in the European Union
- ↑ Purpose and objectives
- ↑ Criteria for membership
- ↑ EGA's Vision 2015
- ↑ Criteria for membership
- ↑
- ↑ B., Kennedy (August 2010). "European Generic Medicines Association (EGA)--16th Annual Conference". IDrugs : the investigational drugs journal. 13 (8): 530–3. PMID 20721822.
- ↑ 7th EGA Annual Symposium on Biosimilar Medicines